查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1667945

二尖瓣疾病市场 - 全球产业规模、份额、趋势、机会和预测，按治疗类型、适应症、最终用户、地区和竞争细分，2020-2030 年预测

Mitral Valve Disease Market - Global Industry Size, Share, Trends, Opportunity, & Forecast, Segmented By Treatment Type, By Indication, By End-User, By Region & Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2024 年全球二尖瓣疾病 (MVD) 市场价值为 32.5 亿美元，预计将经历显着增长，2024 年至 2030 年的年复合成长率(CAGR) 为 8.85%。二尖瓣逆流（MR）和二尖瓣狭窄（MS）等疾病在世界各地普遍存在，为市场发展创造了巨大的机会。这一增长的主要驱动因素包括人口老化、心血管疾病发病率不断上升、医疗技术的不断进步以及对微创治疗方案的需求不断增加。

市场概况
预测期 2026-2030
2024 年市场规模 32.5 亿美元
2030 年市场规模 54.2 亿美元
2025-2030 年复合年增长率 8.85％
成长最快的领域 修復段
最大的市场 北美洲

受诊断和治疗创新以及对微创手术日益增长的偏好推动，该市场预计将经历强劲增长。透过专注于改善患者治疗效果、扩大医疗服务范围和整合尖端技术，MVD 市场可望强劲扩张。随着人们对二尖瓣疾病的认识不断提高，特别是在老年人口中，对​​有效且可获得的治疗方案的需求也在增加，进一步促进了市场的成长。

主要市场驱动因素

二尖瓣疾病 (MVD) 盛行率不断上升

主要市场挑战

治疗费用高昂

主要市场趋势

微创手术的兴起

目录

第 1 章：产品概述

第 2 章：研究方法

第 3 章：执行摘要

第 4 章：顾客之声

第 5 章：二尖瓣疾病市场展望

  • 市场规模和预测
    • 按价值
  • 市场占有率和预测
    • 依治疗类型（修復、置换、心臟再同步治疗、治疗学）
    • 依适应症（狭窄、脱垂、逆流）
    • 按最终使用者（医院、门诊手术中心、其他）
    • 按地区
    • 按公司分类（2024）
  • 市场地图

第 6 章：北美二尖瓣疾病市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 北美：国家分析
    • 加拿大
    • 墨西哥

第 7 章：欧洲二尖瓣疾病市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 欧洲：国家分析
    • 英国
    • 义大利
    • 法国
    • 西班牙

第 8 章：亚太二尖瓣疾病市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 亚太地区：国家分析
    • 印度
    • 日本
    • 韩国
    • 澳洲

第 9 章：南美洲二尖瓣疾病市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 南美洲：国家分析
    • 阿根廷
    • 哥伦比亚

第 10 章：中东和非洲二尖瓣疾病市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • MEA：国家分析
    • 沙乌地阿拉伯
    • 阿联酋

第 11 章：市场动态

  • 驱动程式
  • 挑战

第 12 章：市场趋势与发展

  • 最新动态
  • 产品发布
  • 合併与收购

第 13 章：全球二尖瓣疾病市场：SWOT 分析

第 14 章：波特五力分析

第 15 章：竞争格局

  • Corcym UK Limited
  • Abbott Laboratories Inc
  • Zydus Lifesciences Limited
  • Medtronic plc
  • Edwards Lifesciences Corporation
  • Affluent Medical SA
  • ShockWave Medical, Inc.
  • Valcare Medical
  • Pfizer Inc
  • Teva Pharmaceutical Industries Ltd.

第 16 章：策略建议

第17章 调査会社について・免责事项

简介目录
Product Code: 17684

The global Mitral Valve Disease (MVD) market was valued at USD 3.25 billion in 2024 and is projected to experience significant growth, with a compound annual growth rate (CAGR) of 8.85% from 2024 to 2030. The MVD market is rapidly expanding within the broader cardiovascular devices and treatments sector. Conditions like mitral valve regurgitation (MR) and mitral valve stenosis (MS) are prevalent worldwide, creating substantial opportunities for market development. Key drivers of this growth include an aging population, the increasing prevalence of cardiovascular diseases, continuous advancements in medical technologies, and rising demand for minimally invasive treatment options.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 3.25 Billion
Market Size 2030USD 5.42 Billion
CAGR 2025-20308.85%
Fastest Growing SegmentRepair Segment
Largest MarketNorth America

This market is expected to experience strong growth, fueled by innovations in diagnostics and treatments, alongside a growing preference for minimally invasive procedures. With a focus on improving patient outcomes, expanding access to care, and integrating cutting-edge technologies, the MVD market is poised for robust expansion. As awareness of mitral valve disease increases, particularly in aging populations, the demand for effective and accessible treatment options is also on the rise, further contributing to market growth.

Key Market Drivers

Growing Prevalence of Mitral Valve Disease (MVD)

The rising prevalence of mitral valve disease (MVD) is a primary factor driving the growth of the global MVD market. As MVD becomes more common worldwide, the demand for diagnostic services, treatment options, and healthcare infrastructure tailored to this condition is escalating. Alongside aging, modern lifestyle factors such as obesity, hypertension, diabetes, and smoking are contributing to the higher incidence of MVD. These lifestyle-related conditions are increasingly prevalent, particularly in emerging economies, driving the number of MVD cases.

Obesity is a major global concern, with one in eight individuals living with obesity as of 2022. The prevalence of adult obesity has more than doubled since 1990, with over 890 million adults affected. Hypertension is also widespread, with 1.28 billion adults aged 30 to 79 suffering from the condition, particularly in low- and middle-income countries. This growing incidence of hypertension and obesity directly impacts the prevalence of MVD, placing additional demand on healthcare systems.

The global increase in life expectancy further contributes to the rising incidence of MVD. As people live longer, the likelihood of developing MVD increases, resulting in a larger patient population requiring long-term treatment and management. The global life expectancy is projected to rise from 73.6 years in 2022 to 78.1 years by 2050, which presents both challenges and opportunities for healthcare businesses in addressing the needs of an aging population.

Additionally, as cardiovascular diseases (CVDs) continue to be the leading cause of global mortality, MVD is emerging as a significant contributor to heart failure and related complications. This escalating burden highlights the urgent need for effective diagnostic, treatment, and management solutions for MVD, thus driving market demand.

Key Market Challenges

High Treatment Costs

A major challenge for the growth of the Global Mitral Valve Disease Market is the high cost associated with diagnosis and treatment. Mitral valve diseases often necessitate complex surgical interventions or the implantation of prosthetic valves, which can be prohibitively expensive. Traditional open-heart surgeries and minimally invasive techniques such as transcatheter mitral valve repair (TMVR) both incur significant costs, including surgeon fees, operating room charges, and the cost of prosthetic devices.

Post-operative care and recovery for MVD patients also contribute to high healthcare costs, which include follow-up appointments, medications, and cardiac rehabilitation. In certain regions, inadequate insurance coverage for MVD treatments further compounds the financial burden, potentially deterring patients from seeking timely medical attention and hindering market growth.

Key Market Trends

Rise of Minimally Invasive Procedures

One of the prominent trends in the Global Mitral Valve Disease Market is the increasing adoption of minimally invasive procedures for diagnosing and treating MVD. Traditional open-heart surgery has long been the standard approach, but advances in medical technology have introduced less invasive options, such as transcatheter mitral valve repair (TMVR) and transcatheter mitral valve replacement (TMVR).

Minimally invasive procedures offer several advantages, including smaller incisions, reduced pain, shorter hospital stays, and faster recovery times. These benefits are driving greater patient demand for minimally invasive options, particularly among high-risk or elderly patients who may not be candidates for open-heart surgery. As healthcare professionals gain expertise in performing these procedures, their adoption is expected to continue to rise.

Key Market Players

  • Corcym UK Limited
  • Abbott Laboratories Inc.
  • Zydus Lifesciences Limited
  • Medtronic plc
  • Edwards Lifesciences Corporation
  • Affluent Medical SA
  • ShockWave Medical, Inc.
  • Valcare Medical
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.

Report Scope:

This report segments the Global Mitral Valve Disease Market into the following categories, along with the industry trends:

Mitral Valve Disease Market by Treatment Type:

  • Repair
  • Replacement
  • Cardiac Resynchronization Therapy
  • Therapeutics

Mitral Valve Disease Market by Indication:

  • Stenosis
  • Prolapse
  • Regurgitation

Mitral Valve Disease Market by End-User:

  • Hospitals
  • Ambulatory Surgical Centers
  • Others

Mitral Valve Disease Market by Region:

  • North America: United States, Canada, Mexico
  • Europe: France, United Kingdom, Italy, Germany, Spain
  • Asia-Pacific: China, India, Japan, Australia, South Korea
  • South America: Brazil, Argentina, Colombia
  • Middle East & Africa: South Africa, Saudi Arabia, UAE

Competitive Landscape

This section provides a detailed analysis of major companies in the Global Mitral Valve Disease Market.

Available Customizations:

TechSci Research offers tailored customizations to the Global Mitral Valve Disease market report, providing specific data and insights according to a company's needs. Customization options include:

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Mitral Valve Disease Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Treatment Type (Repair, Replacement, Cardiac Resynchronization Therapy, Therapeutics)
    • 5.2.2. By Indication (Stenosis, Prolapse, Regurgitation)
    • 5.2.3. By End-User (Hospitals, Ambulatory Surgical Centers, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2024)
  • 5.3. Market Map

6. North America Mitral Valve Disease Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Treatment Type
    • 6.2.2. By Indication
    • 6.2.3. By End-User
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Mitral Valve Disease Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Treatment Type
        • 6.3.1.2.2. By Indication
        • 6.3.1.2.3. By End-User
    • 6.3.2. Canada Mitral Valve Disease Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Treatment Type
        • 6.3.2.2.2. By Indication
        • 6.3.2.2.3. By End-User
    • 6.3.3. Mexico Mitral Valve Disease Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Treatment Type
        • 6.3.3.2.2. By Indication
        • 6.3.3.2.3. By End-User

7. Europe Mitral Valve Disease Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Treatment Type
    • 7.2.2. By Indication
    • 7.2.3. By End-User
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Mitral Valve Disease Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Treatment Type
        • 7.3.1.2.2. By Indication
        • 7.3.1.2.3. By End-User
    • 7.3.2. United Kingdom Mitral Valve Disease Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Treatment Type
        • 7.3.2.2.2. By Indication
        • 7.3.2.2.3. By End-User
    • 7.3.3. Italy Mitral Valve Disease Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Treatment Type
        • 7.3.3.2.2. By Indication
        • 7.3.3.2.3. By End-User
    • 7.3.4. France Mitral Valve Disease Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Treatment Type
        • 7.3.4.2.2. By Indication
        • 7.3.4.2.3. By End-User
    • 7.3.5. Spain Mitral Valve Disease Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Treatment Type
        • 7.3.5.2.2. By Indication
        • 7.3.5.2.3. By End-User

8. Asia-Pacific Mitral Valve Disease Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Treatment Type
    • 8.2.2. By Indication
    • 8.2.3. By End-User
    • 8.2.4. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Mitral Valve Disease Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Treatment Type
        • 8.3.1.2.2. By Indication
        • 8.3.1.2.3. By End-User
    • 8.3.2. India Mitral Valve Disease Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Treatment Type
        • 8.3.2.2.2. By Indication
        • 8.3.2.2.3. By End-User
    • 8.3.3. Japan Mitral Valve Disease Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Treatment Type
        • 8.3.3.2.2. By Indication
        • 8.3.3.2.3. By End-User
    • 8.3.4. South Korea Mitral Valve Disease Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Treatment Type
        • 8.3.4.2.2. By Indication
        • 8.3.4.2.3. By End-User
    • 8.3.5. Australia Mitral Valve Disease Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Treatment Type
        • 8.3.5.2.2. By Indication
        • 8.3.5.2.3. By End-User

9. South America Mitral Valve Disease Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Treatment Type
    • 9.2.2. By Indication
    • 9.2.3. By End-User
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Mitral Valve Disease Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Treatment Type
        • 9.3.1.2.2. By Indication
        • 9.3.1.2.3. By End-User
    • 9.3.2. Argentina Mitral Valve Disease Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Treatment Type
        • 9.3.2.2.2. By Indication
        • 9.3.2.2.3. By End-User
    • 9.3.3. Colombia Mitral Valve Disease Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Treatment Type
        • 9.3.3.2.2. By Indication
        • 9.3.3.2.3. By End-User

10. Middle East and Africa Mitral Valve Disease Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Treatment Type
    • 10.2.2. By Indication
    • 10.2.3. By End-User
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Mitral Valve Disease Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Treatment Type
        • 10.3.1.2.2. By Indication
        • 10.3.1.2.3. By End-User
    • 10.3.2. Saudi Arabia Mitral Valve Disease Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Treatment Type
        • 10.3.2.2.2. By Indication
        • 10.3.2.2.3. By End-User
    • 10.3.3. UAE Mitral Valve Disease Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Treatment Type
        • 10.3.3.2.2. By Indication
        • 10.3.3.2.3. By End-User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. Global Mitral Valve Disease Market: SWOT Analysis

14. Porter's Five Forces Analysis

15. Competitive Landscape

  • 15.1. Corcym UK Limited
    • 15.1.1. Business Overview
    • 15.1.2. Product & Service Offerings
    • 15.1.3. Recent Developments
    • 15.1.4. Financials (If Listed)
    • 15.1.5. Key Personnel
    • 15.1.6. SWOT Analysis
  • 15.2. Abbott Laboratories Inc
  • 15.3. Zydus Lifesciences Limited
  • 15.4. Medtronic plc
  • 15.5. Edwards Lifesciences Corporation
  • 15.6. Affluent Medical SA
  • 15.7. ShockWave Medical, Inc.
  • 15.8. Valcare Medical
  • 15.9. Pfizer Inc
  • 15.10.Teva Pharmaceutical Industries Ltd.

16. Strategic Recommendations

17. About Us & Disclaimer